About NUTRI PHARMA AS
NUTRI PHARMA AS is a Private Limited Company and was incorporated on Jun 30, 2010 in Norway. Its corporate identification number is (CIN) 995765497 and its current status is Active.
Key Metrics
CIN
995765497
Current Status
Active
Entity Type
Private Limited Company
Date Of Incorporation
Jun 30, 2010
Contact Details for NUTRI PHARMA AS
- Registered Address
- Dronning Mauds gate 15, 0250, OSLO
Brands associated with NUTRI PHARMA AS
There is one brand associated with NUTRI PHARMA AS which include Bionor Holding .
Name | Short Description | Founded Year | Location | Current Stage |
|---|---|---|---|---|
Developer of peptide vaccines for treating HIV | 1985 | Unfunded |
Financials of NUTRI PHARMA AS
Board of Directors and Signatories of NUTRI PHARMA AS
Board of Directors of NUTRI PHARMA AS
Here is the list of current board of directors of NUTRI PHARMA AS:
Name | Designation | Status | Appointment Date | Duration |
|---|---|---|---|---|
- | Current | Nov 09, 2022 | 3 Years 8 Months | |
- | Current | Nov 09, 2022 | 3 Years 8 Months |
Note: Limited amount of data is shown here. To access all the data Buy Documents
Competitors & Alternates of NUTRI PHARMA AS
Bionor Holding is the only brand associated with NUTRI PHARMA AS, and here are its Top 10 competitors ranked by Tracxn score:
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  ImmunityBio 2014, El Segundo (United States), Public | Developer of peptide-based vaccines for immunotherapy | $169M | 67/100 | |
2nd | Antheia 2013, Palo Alto (United States), Series C | Genetically engineered yeast cells to produce medicinal products | $176M | 67/100 | |
3rd | Transcenta 2019, Suzhou (China), Public | Developer of antibody-based therapeutics | $205M | 66/100 | |
4th | Developer of antibody drug conjugates for the treatment of broad spectrum diseases | $195M | 65/100 | ||
5th | Korro Bio 2018, Cambridge (United States), Public | Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases | $4M | 64/100 | |
6th | Developer of vaccines against constantly mutating pathogens | $42.2M | 63/100 | ||
7th |  Brii Biosciences 2018, San Francisco (United States), Public | Developer of biologics to treat hepatitis B infection | $415M | 63/100 | |
8th | Fermentalg 2005, Libourne (France), Public | Innovating with algae for sustainable solutions in nutrition and environmental impact | $30.3M | 63/100 | |
9th | Microban 1994, Huntersville (United States), Acquired | Antimicrobial and odor control technologies for durable product protection and freshness | $64.6M | 63/100 | |
10th | Dewpoint Therapeutics 2018, Boston (United States), Series D | Developer of small molecule based therapeutics | $364M | 62/100 | |
793rd | Bionor Holding 1985, Oslo (Norway), Unfunded | Developer of peptide vaccines for treating HIV | - | - | 29/100 |
_1523881431192.png?devicePixelRatio=2&height=30&width=30){kind=logo}
News related to NUTRI PHARMA AS
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Attribution:
© Brønnøysund Register Centre
FAQs about NUTRI PHARMA AS
Explore our recently published Legal Entities
